Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD and Ponatinib in Ph+ or BCR-ABL+ ALL
NCT01424982Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2011
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2011; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT01424982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01424982.